Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Related Posts

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

In a landmark ruling that will have far-reaching implications for the pharmaceutical sector, the High Court of Himachal Pradesh has quashed three criminal complaints filed by the Central Drugs Standard…

Eli Lilly launches cancer drug Tanstrive in India

New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

Eli Lilly launches cancer drug Tanstrive in India

Eli Lilly launches cancer drug Tanstrive in India

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Centre eases BIS quality compliance with new risk-based framework for manufacturers

Centre eases BIS quality compliance with new risk-based framework for manufacturers

SS Innovations International aces Race beating Global Giants in Surgical Robotics

SS Innovations International aces Race beating Global Giants in Surgical Robotics

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility